z-logo
Premium
Linking αMSH with PPARγ in B16‐F10 melanoma
Author(s) -
Maresca Vittoria,
Flori Enrica,
Camera Emanuela,
Bellei Barbara,
Aspite Nicaela,
Ludovici Matteo,
Catricalà Caterina,
Cardinali Giorgia,
Picardo Mauro
Publication year - 2013
Publication title -
pigment cell and melanoma research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.618
H-Index - 105
eISSN - 1755-148X
pISSN - 1755-1471
DOI - 10.1111/j.1755-148x.2012.01042.x
Subject(s) - peroxisome proliferator activated receptor , receptor , signal transduction , endocrinology , nuclear receptor , medicine , transcription factor , melanocyte stimulating hormone , chemistry , microbiology and biotechnology , forskolin , biology , cancer research , biochemistry , gene
Summary We have discovered a new α‐melanocyte stimulating hormone (α‐MSH)/peroxisome proliferator activated receptor‐γ (PPAR‐γ) connection in B16‐F10 cells. Both PPAR‐γ up‐regulation and its induction as an active transcription factor were observed in response to α‐MSH. The α‐MSH/PPAR‐γ connection influenced both pigmentation and proliferation. The forskolin‐stimulated cAMP/PKA pathway was not able to induce either PPAR‐γ translocation into the nucleus or PPAR‐γ transcriptional activity. As the melanocortin‐1 receptor, the specific receptor for the α‐MSH, is a G‐protein coupled receptor, we wondered whether the phosphatidylinositol [PI(4,5)P 2 /PLC β ] signal pathway was involved in mediating the α‐MSH‐dependent PPAR‐γ activation. Employing inhibitors of PI(4,5)P 2 /PLC β pathway, the results of our experiments suggested that this pathway was promoted by α‐MSH and that α‐MSH played a role in mediating PPAR‐γ activation. We have demonstrated, for the first time, that α‐MSH induces the PI(4,5)P 2 /PLC β pathway, through analysis of the basic steps of the pathway. The α‐MSH effect on PPAR‐γ was independent of animal species and was not correlated with the physio‐pathological status.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here